6h agoGuruFocusBEARISH 42Earnings
Archived explainer. For the current picture see today's ALNY page.
Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Down Today?
By the Top Tier Newswire AI Desk · October 29, 2026 at 12:36 PM ET · reviewed against 23 wire stories
ALNYLAM PHARMACEUTIC (ALNY) is down -22.30% in the latest session. Our newswire has captured 23 stories on ALNY across 7 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Alnylam Pharmaceuticals shares fell 22.30% to $180.57 on Wednesday. The sharp decline followed the release of third-quarter results that beat estimates but were accompanied by slowing US sales growth for Amvuttra and Onpattro, along with pipeline delays.
What Happened
Alnylam reported third-quarter adjusted earnings per share of $16.26 and total sales of $1.458 billion, exceeding the consensus estimate of $1.434 billion. Despite the beat, the company affirmed its full-year 2026 sales guidance of $5.275 billion to $5.725 billion. The stock reacted negatively to concerns regarding slowing demand for its US Amvuttra and Onpattro products and rising costs. Analysts also noted delays in clinical data announcements. Stifel downgraded the stock, citing slowing growth and slower pipeline progress, while H.C. Wainwright argued the selloff on payer restrictions was overdone. The company also announced positive initial Phase 1b data for brezosiran in Huntington's disease.
What The Data Shows
The stock opened at $238.00, a 2.4% gap up from the prior close of $232.40. It reached a session high of $242.00 at 8:00 AM ET before dropping to a session low of $179.87 at 9:30 AM ET. Volume reached 4.5 million shares, which is 2.7 times the three-month daily average. The stock printed a fresh 52-week low on October 29, 2026. The 52-week range is currently $197.81 to $484.61. Over the last eight sessions, the stock has declined 17.2%. Bryan Supran, the company's EVP, CLO, and Secretary, sold shares on October 2, 2026. Recent insider filings show one sale totaling $399,000 in the last 90 days. Congressional trades in the last 90 days include three buys and two sells, with the most recent filing on October 8, 2026.
What To Watch
Investors will monitor the company's response to the slowing US sales growth and the impact of CMS 340B reimbursement rule concerns on future revenue. The breadth of analyst coverage, including the recent downgrade from Stifel, will also be a key factor in near-term price action.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ALNY by the numbers
Last: $180.57Session: -22.30%7 sessions: -17.16%Coverage: 23 stories / 7 sourcesAI sentiment: 49/100 (mixed)Mkt cap: $30.3BP/E: 41.452w: $197.81 to $484.61
The headlines behind the move
6h agoGuruFocusBEARISH 31General
Alnylam Pharmaceuticals (ALNY) Shares Drop 14% After Clinical Data Delays Announcement
6h agoGuruFocusBEARISH 34General
Alnylam (ALNY) Shares Drop Amid CMS 340B Reimbursement Rule Concerns
7h agoInvesting.com Analyst RatingsBEARISH 34Analyst
Stifel downgrades Alnylam stock rating on Amvuttra concerns
Stifel downgrades Alnylam stock rating on Amvuttra concerns
7h agoSeeking AlphaBEARISH 34Earnings
Alnylam falls despite earnings beats as US Amvuttra, Onpattro sales growth slows
Alnylam stock plunged after Q3 earnings beat as US Amvuttra demand slowed and costs rose. Read more here.
7h agoGuruFocusBEARISH 38Earnings
Alnylam Pharmaceuticals (ALNY) Reports Q3 Results with Pipeline Delays and Maintains Hold Rating
7h agoThe FlyBULLISH 63Analyst
Alnylam selloff on payer restrictions overdone, says H.C. Wainwright
7h agoThe FlyBEARISH 34Analyst
Alnylam downgraded at Stifel on slowing growth, slower pipeline progress
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on ALNY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier ALNY move explainers: 2026-10-29 · 2026-09-02 · 2026-08-27 · 2026-07-31 · 2026-07-30 · 2026-07-17